ArticleMycoses2026
CT-Based Clinical-Radiomics for Differentiating Talaromyces marneffei Spondylitis From Tuberculous Spondylitis Before Pathogen Confirmation: A Multicentre Diagnostic Study in an Endemic Region.
Article in Mycoses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundTalaromyces marneffei spondylitis (TMS) is an uncommon but clinically important form of talaromycosis in endemic regions. Where talaromycosis and tuberculosis overlap, TMS may be worked up as tuberculous spondylitis (TBS), delaying fungal investigations and antifungal treatment.
objectivesTo assess whether pretreatment CT, routine clinical variables and radiomics features can help differentiate TMS from TBS at the initial assessment stage. PATIENTS/
methodsThis retrospective multicentre study included 263 patients meeting the prespecified composite reference standard (83 TMS and 180 TBS). Centre A formed the training and internal-validation cohorts; Centres B and C formed the external cohort (n = 50; 16 TMS and 34 TBS). Six clinical variables and 14 CT radiomics features were used to develop clinical, radiomics and combined models.
resultsTMS showed a stronger systemic inflammatory phenotype, whereas TBS generally showed more frequent disc-endplate involvement and osseous destruction. The clinical-radiomics model achieved the highest AUCs in the training, internal validation and external validation cohorts: 0.958 (95% CI, 0.924-0.992), 0.940 (95% CI, 0.871-1.000) and 0.927 (95% CI, 0.867-0.987), respectively. The external confidence interval was wide, reflecting the limited external sample size.
conclusionsIn regions where talaromycosis and tuberculosis overlap, a pretreatment CT-based clinical-radiomics approach may help flag patients in whom TMS should be considered early. This approach could support earlier fungal investigations while definitive microbiological, molecular or histopathological results are pending. It addresses only the TMS-versus-TBS differential and is not a general spinal-infection triage tool; the findings support further evaluation in endemic settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.